Business Trends

May 01, 2005
BioPharm International
By BioPharm International Editors
Conversion of facilities from one use to another is a positive trend that keeps good paying jobs in local communities.
May 01, 2005
BioPharm International
By BioPharm International Editors
Geron rose 7% and StemCells 15% . . . when news of the New York capital funding effort hit the business pages.
May 01, 2005
BioPharm International
Three meetings of the BioPharma Operations Excellence Consortium, facilitated by Tefen Operations Management Consulting, were held recently. The east coast meeting was hosted by Genzyme at its headquarters in Cambridge, MA; the west coast Chapter met at the Genentech campus in South San Francisco, CA; and the European forum held its meeting in Frankfurt, hosted by Aventis.
May 01, 2005
BioPharm International
By BioPharm International Editors
Your company's job is to make biopharmaceutical products. Managing facilities is a function supporting the main task. General manufacturing companies discovered this long ago, but pharmaceutical producers have been lagging. Once you consider the outsouring of non-core activities like facility management (FM), office services, space planning, and utilities management, you can focus on core business functions that make profits.
May 01, 2005
BioPharm International
Cancer remains the primary indication (three products), again mirroring recent approval trends.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
Out-licensing has become a crucial part of most biotech companies' business strategies.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
With biotech valuations at the lowest point in years, the resulting investment opportunities are multiplying — seemingly by the hour.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
Biotechnology and life sciences companies come in all shapes and sizes. Some are multinational companies with vast resources and others are small companies working with a few new compounds. Regardless of size or market position, these companies should all have one common question of those that handle their insurance: Will their current insurance program protect their assets and investments in the event of a significant loss? Understanding the nature of risks, acquiring suitable insurance, and comprehending policy issues when claims arise are essential to protecting assets and obtaining reimbursement when losses occur.
Apr 01, 2005
BioPharm International
By BioPharm International Editors
Outsourcing is becoming increasingly widespread and essential in the biopharmaceutical industry. Its imprint on biotech world business and on the development of biopharmaceutical drugs is becoming ever more pronounced. It is estimated that almost one-half of biopharmaceutical companies contract out at least part of the production of their products. On the other hand, those companies that do not outsource production often contract out some of their development activities.
Mar 01, 2005
BioPharm International
By BioPharm International Editors
A tepid currency picture may cause biopharm companies to put the breaks on initiatives in places like information systems, research and development, and even hiring.
native1_300x100
lorem ipsum